Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | KN046 |
Synonyms | |
Therapy Description |
KN046 is a bispecific monoclonal antibody that targets PD-L1 (CD274) expressed on tumor cells and CTLA-4 on T lymphocytes, potentially leading to enhanced antitumor immune response (PMID: 37263673). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
KN046 | KN 046|KN-046|Erfonrilimab | CTLA4 Antibody 33 Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 124 | KN046 is a bispecific monoclonal antibody that targets PD-L1 (CD274) expressed on tumor cells and CTLA-4 on T lymphocytes, potentially leading to enhanced antitumor immune response (PMID: 37263673). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04925947 | Phase II | KN046 | Phase II Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors | Terminated | USA | 0 |